During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib (Piqray), polatuzumab vedotin-piiq (Polivy), selinexor (Xpovio), and darolutamide (Nubeqa)—for treating certain patients with a wide...
Cancer is very complex, and the tools that we need to understand how it develops and progresses come from many different scientific fields. Integrative Molecular Epidemiology, known as IME, brings together epidemiologists, data scientists,...
As a monthly staple on this blog, we feature the editors’ picks from the 10 journal issues published by the American Association for Cancer Research (AACR). This month, selections include two articles detailing laboratory...
A study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression of prostate cancer.
This spring, in the inaugural year of the American Association for Cancer Research (AACR) Global-Scholar-In-Training Awards (GSITA) program, 15 young researchers from around the world arrived in Atlanta eager to share their knowledge and...
Understanding brain metastasis risk could influence screening, surveillance practices, a study of breast cancer, lung cancer, and melanoma patients found.
Since 2011, immunotherapy has emerged as an exciting new approach to cancer treatment that is yielding unprecedented, durable responses for patients with an increasingly diverse array of cancer types. Much of the excitement has...
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to efficiently answer important clinical, research, and regulatory questions around oncology treatments and outcomes. RWD can...
Rare cancers, when taken all together, make up an estimated 20 to 25 percent of all cancers diagnosed. With more than 1.7 million people in the U.S. expected to be diagnosed with cancer this year, that could mean as many as 400,000 people will learn they have a rare cancer. Often, these patients have few treatment options.
Every two minutes, a woman somewhere in the world dies of cervical cancer. That harrowing statistic, shared by Anna R. Giuliano, PhD, founding director of the Center for Immunization and Infection Research in Cancer at...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More